| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| OACCOaktree Acquisition Corp. III Life Sciences | 209.7M | 10.60 | 195.57 | 0% | 0.00 | |||
| AFJKAimei Health Technology Co., Ltd | 281.66M | 46.01 | 164.32 | 3.35% | 0.00 | |||
| OACCWOaktree Acquisition Corp. III Life Sciences | 0.93 | 17.12 | 0.71% | 0.00 | ||||
| DMAADrugs Made In America Acquisition Corp. Ordinary Shares | 348.58M | 10.40 | -185.71 |
| Dec 2024 | |
|---|---|
| Net Interest Income | 0 |
| NII Growth % | - |
| Net Interest Margin % | - |
| Interest Income | 0 |
| Interest Expense | 0 |
| Loan Loss Provision | 0 |
| Non-Interest Income | 0 |
| Non-Interest Income % | - |
| Total Revenue | 0 |
| Revenue Growth % | - |
| Non-Interest Expense | 480 |
| Efficiency Ratio | - |
| Operating Income | -479 |
| Operating Margin % | - |
| Operating Income Growth % | - |
| Pretax Income | -479 |
| Pretax Margin % | - |
| Income Tax | 0 |
| Effective Tax Rate % | - |
| Net Income | -479 |
| Net Margin % | - |
| Net Income Growth % | - |
| Net Income (Continuing) | -479 |
| EPS (Diluted) | -0.06 |
| EPS Growth % | - |
| EPS (Basic) | -0.06 |
| Diluted Shares Outstanding | 8.57M |
| Dec 2024 | |
|---|---|
| Cash & Short Term Investments | 1.35K |
| Cash & Due from Banks | 1.35K |
| Short Term Investments | 0 |
| Total Investments | 0 |
| Investments Growth % | - |
| Long-Term Investments | 0 |
| Accounts Receivables | 0 |
| Goodwill & Intangibles | - |
| Goodwill | 0 |
| Intangible Assets | 0 |
| PP&E (Net) | 0 |
| Other Assets | 546 |
| Total Current Assets | 4.99K |
| Total Non-Current Assets | 546 |
| Total Assets | 551 |
| Asset Growth % | - |
| Return on Assets (ROA) | -0.87% |
| Accounts Payable | 0 |
| Total Debt | 662 |
| Net Debt | 661 |
| Long-Term Debt | 0 |
| Short-Term Debt | 662 |
| Other Liabilities | 0 |
| Total Current Liabilities | 796 |
| Total Non-Current Liabilities | 0 |
| Total Liabilities | 796 |
| Total Equity | -244 |
| Equity Growth % | - |
| Equity / Assets (Capital Ratio) | - |
| Return on Equity (ROE) | - |
| Book Value per Share | -0.00 |
| Tangible BV per Share | - |
| Common Stock | 986 |
| Additional Paid-in Capital | 34 |
| Retained Earnings | -279 |
| Accumulated OCI | 0 |
| Treasury Stock | 0 |
| Preferred Stock | 0 |
| Dec 2024 | |
|---|---|
| Cash from Operations | -172.26K |
| Operating CF Growth % | - |
| Net Income | -479 |
| Depreciation & Amortization | 0 |
| Deferred Taxes | 0 |
| Other Non-Cash Items | -171.92K |
| Working Capital Changes | 132 |
| Cash from Investing | 0 |
| Purchase of Investments | 0 |
| Sale/Maturity of Investments | 0 |
| Net Investment Activity | - |
| Acquisitions | 0 |
| Other Investing | 0 |
| Cash from Financing | 173.62K |
| Dividends Paid | 0 |
| Share Repurchases | 0 |
| Stock Issued | -328.6K |
| Net Stock Activity | - |
| Debt Issuance (Net) | 502.21K |
| Other Financing | 0 |
| Net Change in Cash | 1.35K |
| Exchange Rate Effect | 0 |
| Cash at Beginning | 0 |
| Cash at End | 1.35K |
| Interest Paid | 0 |
| Income Taxes Paid | 0 |
| Free Cash Flow | -295 |
| FCF Growth % | - |
| Metric | 2024 |
|---|---|
| Return on Assets (ROA) | -86.96% |
| Net Interest Margin | 0% |
| Equity / Assets | -44.28% |
| Book Value / Share | -0 |
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) grew revenue by 0.0% over the past year. Growth has been modest.
Yes, Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is profitable, generating $5.7M in net income for fiscal year 2024.
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a net interest margin (NIM) of N/A. NIM has been under pressure due to interest rate environment.
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has an efficiency ratio of 0.0%. This is excellent, indicating strong cost control.